Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Oral salmon calcitonin, salmon calcitonin
salmon calcitonin, salmon calcitonin · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Oral salmon calcitonin, salmon calcitonin nasal spray | DRUG | - |
| Oral salmon calcitonin | DRUG | - |
Inclusion Criteria: * Medical history and symptoms of knee osteoarthritis Exclusion Criteria: * Any other disease or medication affecting the bone or cartilage. * Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering t...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Salmon calcitonin is being studied for osteoarthritis and postmenopausal osteoporosis. The clinical program has focused on oral formulations of the hormone, with Phase 1 trials conducted in patients with osteoarthritis and in healthy postmenopausal women. It is a musculoskeletal therapeutic developed by Novartis AG.
Salmon calcitonin targets CALCR, the calcitonin receptor, and acts as an agonist at that receptor. This receptor is involved in calcium regulation and bone metabolism, which is the basis for studying the drug in postmenopausal osteoporosis and osteoarthritis.
Novartis AG, which trades under the ticker NVS, is the developer of salmon calcitonin. The company has sponsored the clinical studies of the oral formulation in osteoarthritis and postmenopausal osteoporosis.
Salmon calcitonin is in Phase 1 clinical development. It is investigational and has not been approved. The completed Phase 1 trials evaluated pharmacokinetics, pharmacodynamics, absorption, efficacy and tolerance, with a total enrollment of 142 participants across the studies.
Four completed Phase 1 trials have studied salmon calcitonin: NCT00486369 and NCT00486317 in osteoarthritis, and NCT00411125 and NCT00395395 in healthy postmenopausal women. All were conducted in Denmark. Two were randomized and double blind, and enrollment in the two osteoporosis studies was 86 and 56 participants respectively.
Yes. Oral salmon calcitonin and salmon calcitonin nasal spray are alternative names for salmon calcitonin, referring to different formulations of the same hormone. The clinical trials listed here used the oral formulation in osteoarthritis and postmenopausal osteoporosis.